The therapeutic landscape of obesity and T2D has been profoundly transformed by the emergence of incretin-based pharmacotherapies, particularly GLP-1 RAs and, more recently, dual and triple agonists targeting GLP-1, GIP, and GCG receptors. The gene discussed is GIP; the disease is obesity disorder.